

Gregory F Guzauskas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6747714/publications.pdf>

Version: 2024-02-01

27
papers

267
citations

1307366
7
h-index

940416
16
g-index

27
all docs

27
docs citations

27
times ranked

427
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. <i>Genetics in Medicine</i> , 2022, 24, 1017-1026.	1.1	13
2	Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 455-468.	0.5	8
3	Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 615-624.	0.5	0
4	THE AUTHORS RESPOND. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1141-1141.	0.5	0
5	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. <i>Journal of Medical Economics</i> , 2021, 24, 363-372.	1.0	8
6	Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer. <i>Journal of Medical Economics</i> , 2021, 24, 1309-1317.	1.0	0
7	Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 455-468.	0.5	1
8	Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. <i>Pharmacoeconomics</i> , 2020, 38, 171-179.	1.7	0
9	The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1072-1076.	0.5	1
10	The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 620-623.	0.5	6
11	Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. <i>JAMA Network Open</i> , 2020, 3, e2022874.	2.8	44
12	Cost-effectiveness of population genomic screening. <i>Genetics in Medicine</i> , 2019, 21, 2840-2841.	1.1	6
13	Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. <i>Value in Health</i> , 2019, 22, 988-994.	0.1	2
14	Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. <i>Journal of Medical Economics</i> , 2019, 22, 1006-1013.	1.0	22
15	Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. <i>Leukemia and Lymphoma</i> , 2019, 60, 1668-1676.	0.6	5
16	Economic evaluation of telephone-based concussion management for combat-related mild traumatic brain injury. <i>Journal of Telemedicine and Telecare</i> , 2018, 24, 282-289.	1.4	8
17	HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE. <i>Neuro-Oncology</i> , 2018, 20, vi116-vi117.	0.6	0
18	HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi116-vi116.	0.6	0

#	ARTICLE	IF	CITATIONS
19	HOUT-17. ELDERLY PATIENTS >65YEARS OF AGE WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME GAIN LIFE TIME FROM TREATMENT WITH TUMOR TREATING FIELDS AND TEMOZOLOMIDE. Neuro-Oncology, 2018, 20, vi116-vi116.	0.6	1
20	The Authors Respond. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 712-713.	0.5	0
21	Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. CNS Oncology, 2018, 7, CNS23.	1.2	18
22	Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of Medical Economics, 2018, 21, 960-967.	1.0	4
23	What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?. International Journal of Stroke, 2017, 12, 137-144.	2.9	5
24	Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology, 2017, 6, 53-61.	0.7	6
25	Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 939-947.	0.5	44
26	What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?. Blood, 2016, 128, 3605-3605.	0.6	5
27	Cost-Effectiveness of Recombinant Tissue-Type Plasminogen Activator Within 3 Hours of Acute Ischemic Stroke. Stroke, 2014, 45, 3032-3039.	1.0	60